文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

病毒学抑制的HIV感染者换用BIC/TAF/FTC或DTG+TDF/FTC的真实世界结局与替诺福韦耐药影响

Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究基于法国Dat'AIDS队列,纳入9827例病毒学抑制的HIV感染者,其中1393例换用BIC/TAF/FTC或DTG+TDF/FTC。

要点

  • 病毒学抑制者换用BIC/TAF/FTC或DTG+TDF/FTC后病毒学失败风险无显著增加。
  • 替诺福韦耐药及M184V/I突变未影响换药后的病毒学失败风险。
  • 多数病毒学失败为短暂低病毒血症或与依从性问题相关。

核心结论

  • 真实世界中,病毒学抑制的HIV感染者换用BIC/TAF/FTC或DTG+TDF/FTC与病毒学失败风险无显著关联。
  • 替诺福韦耐药及M184V/I突变对换药后病毒学失败无影响。

研究设计与样本

  • 法国国家Dat'AIDS队列(NCT02898987)分析,纳入2014年1月1日后随访、无DTG和BIC暴露史或耐药、病毒载量<50 copies/mL持续超过12个月的HIV感染者。
  • 共纳入9827例,其中1393例(14.2%)换用BIC/TAF/FTC或DTG+TDF/FTC。
  • 采用边际结构模型模拟目标试验比较换药者与非换药者的病毒学失败风险,并用多变量Cox模型评估换药者中替诺福韦耐药与病毒学失败的关系。

主要发现

  • 换药者中观察到75例(5.4%)病毒学失败,非换药者中523例(6.2%)。

临床怎么用

  • 对于病毒学抑制的HIV感染者,可考虑换用BIC/TAF/FTC或DTG+TDF/FTC,无需过度担忧替诺福韦耐药或M184V/I突变导致的病毒学失败。
  • 换药后出现病毒学失败时,应评估依从性,多数失败为短暂低病毒血症或与未测量的依从性问题相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated whether switching to bictegravir/tenofovir alafenamide/emtrictabine (BIC/TAF/FTC) or dolutegravir (DTG)/tenofovir disoproxil fumarate (TDF)/FTC in people with human immunodeficiency virus (PWH) with virological success increased risks of virological failure (VF), and if VF was driven by tenofovir resistance. METHODS: Analysis embedded in the French national Dat'AIDS cohort (NCT02898987) of all PWH followed after 1 January 2014, with no history of DTG and BIC exposure or resistance, and with a viral load <50 copies/mL for more than 12 months. Switchers changed their antiretroviral regimen to BIC/TAF/FTC or DTG + TDF/FTC. VF defined as 1 value >200 copies/mL. Marginal structural models compared VF in switchers and nonswitchers, emulating a target trial. A multivariate Cox model assessed tenofovir resistance with VF in switchers only. RESULTS: There was a total of 9827 PWH, of whom 1393 (14.2%) switched to BIC/TAF/FTC or DTG + TDF/FTC. We observed 75 (5.4%) VF in switchers and 523 (6.2%) in nonswitchers. After weighing, switching was associated with a nonsignificant risk of VF (hazard ratio [HR] 1.29; 95% CI: .97-1.7) (P = .08). Presence of possible resistance and resistance to tenofovir (ANRS resistance algorithm) was not associated with VF (HR 1.12; 95% CI: .82-1.5; P = .47) In switchers only, tenofovir resistance was not associated with VF (HR 1.04; 95% CI: .47-2.33), nor was M184V or M184I mutations (HR 0.98; 95% CI: .5-2.1). CONCLUSIONS: In a real-world setting, switching to BIC/TAF/FTC or DTG + TDF/FTC in PWH with virological success was associated with a nonsignificant risk of VF, but M184V or M184I mutations and tenofovir resistance had no effect on VF. Most VF were blips or related to unmeasured adherence issues.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Makinson A, Bani-Sadr F, Palich R, et al. Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance. Clin Infect Dis. 2026. PMID: 41511917. doi:10.1093/cid/ciaf726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。